ERCC1 and BRCA1 mRNAs expression levels in malignant pleural and peritoneal effusions are associated with chemosensitivity to cisplatin in vitro
10.3781/j.issn.1000-7431.2010.03.011
- VernacularTitle:恶性胸腔和腹腔积液中ERCC1和BRCA1 mRNA的表达水平与顺铂敏感性的关系
- Author:
Lifeng WANG
;
Haitao YIN
;
Xiaoping QIAN
;
Wenjing HU
;
Zhengyun ZOU
;
Lixia YU
;
Baorui LIU
- Publication Type:Journal Article
- Keywords:
Carcinoma;
Pleural effusion,malignant;
Ascites,malignant;
Nucleotide excision repair;
Gene,ERCC1;
Gene,BRCA1;
Cisplatin;
Drug screening assays,antitumor
- From:
Tumor
2010;(3):226-231
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The aim of this study was to investigate the association of mRNA expressions of ERCC1 (excision repair cross-complementing group 1) and BRCA1 (breast cancer 1) with chemosensitivity to cisplatin in malignant pleural and peritoneal effusions.Methods:Malignant pleural and peritoneal effusions were collected from 46 patients diagnosed with stage Ⅳ malignant tumor, prospectively. The tumor cells were isolated and the sensitivity of tumor cells to cisplatin was detected by adenosine triphosphate-bioluminescence assay (ATP-TCA). Real-time quantitative PCR was used to determine the mRNA expressions of ERCC1 and BRCA1. Results:The expression level of ERCC1 mRNA was negatively correlated with sensitivity of non-small cell lung cancer (NSCLC) to cisplatin (P= 0.001, r=0.685). BRCA1 mRNA expression level had negative correlation with sensitivity to cisplatin in both NSCLC (P=0.014, r=0.541) and gastric cancer (P=0.002, r=0.625). A significant interaction was found between the effects of ERCC1 and BRCA1 mRNA expressions on sensitivity to cisplatin (P=0.010 for all patients;P=0.027 for gastric cancer patients).Conclusion:ERCC1 and BRCA1 mRNA expression levels correlated with ex vivo chemosensitivity of tumor cells to cisplatin in malignant pleural and peritoneal effusions. Detection of both ERCC1 and BRCA1 may have a higher reliability in predicting the sensitivity of tumor cells to cisplatin than detection of single ERCC1 or BRCA1 expression.
